			Home About us Contact

Infusion Time (infusion + time)

Distribution by Scientific Domains

Medical Sciences	75%

Selected Abstracts

EFFECTS OF ENZYME-AIDED PEELING ON THE QUALITY OF LOCAL MANDARIN (CITRUS RETICULATA B.) SEGMENTS

JOURNAL OF FOOD PROCESSING AND PRESERVATION, Issue 5 2004
FANNY LIU
ABSTRACT Pectinases are observed to selectively alter the albedo structure of citrus fruits and, hence, aid the removal of the peel and adhering albedo layer. This study was carried out to determine the optimum conditions needed to peel local mandarins using pectinases (Peelzym II, Novo Nordisk, Denmark). The experiment variables were enzyme concentration, vacuum pressure and vacuum infusion time. The mandarins were first scored from the stem end to the blossom end, followed by immersion in 1000 mL of enzyme solution at a set vacuum pressure and ambient temperature (27 ± 1C). Only one parameter was varied in any one experiment. Peelzym II at 0.4% v/w, 650 mm Hg vacuum and 16 min of vacuum time were optimal. The enzyme-peeled fruit segments were judged by the panelists using three different sensory tests to ascertain their appeal to consumers. A significant (P < 0.05) difference between enzyme-peeled and hand-peeled segments was found, with the panelists preferring the enzyme-peeled segments. [source]

A comparative study of vacuum-assisted resin transfer molding (VARTM) for sandwich panels

POLYMER COMPOSITES, Issue 6 2003
J. Dai
Vacuum-assisted resin transfer molding (VARTM) of sandwich panels can be facilitated by using high permeability layers (HPL) over the skins or adding channels in the surfaces of the core (CIC). The present paper investigates the advantages and disadvantages of both methods in terms of manufacturing cost and time through simulations and experimental observations. A cost model is developed, and the resin infusion time for each method was minimized through simulations. The design parameters are the number of high-permeability layers and the number and size of channels. A penalty function with equal weight on cost and time is used to find the optimum values of the design parameters. Under the conditions studied, the optimal HPL method is found to be better than the optimal CIC method. While the conclusion is limited to the present study, the proposed approach can be used to optimize manufacturing processes for larger sandwich panels under different conditions. [source]

Study to support the standardization of the prescribing, dispensing and labeling of etoposide formulations in Australia

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Issue 3 2010
Christine CARRINGTON
Abstract Aim: Etoposide is used in a wide variety of solid and hematological tumors. It is available in Australia in two intravenous formulations; etoposide base and the etoposide phosphate salt with 113.6 mg of etoposide phosphate being equivalent to 100 mg of the etoposide base. Variances between the etoposide dose prescribed and that actually given have been reported recently in Australia with patients receiving either too much or too little of the intended dose of etoposide. We carried out a review of national practices of prescribing, dispensing and labeling of etoposide and etoposide phosphate. Methods: Cancer care clinicians and pharmacists, identified through their membership of the Clinical Oncological Society of Australia (COSA), were asked to complete an online survey or participate in a telephone interview, about their etoposide prescribing and dispensing practices. Results: Nineteen pharmacists and 11 prescribers provided responses suitable for analysis. The most common reason for using the etoposide phosphate formulation was its shorter infusion time. The most common reason provided for preferring the base formulation over the phosphate formulation was that the original clinical trial data supported its use. There were a variety of methods identified that a prescriber might use to indicate the formulation of etoposide required and a variety of methods used for the labeling of etoposide formulations. Conclusion: Prescribing, ordering and dispensing practices for etoposide base and etoposide phosphate are inconsistent across Australia, which could lead to dosing errors. We recommend that a national standard is adopted with etoposide phosphate preparations prescribed and labeled as "Etoposide (as the PHOSPHATE) x mg. Where x is the number of milligrams of etoposide base required." This would move towards minimizing the risk of dosage errors occurring with these formulations. [source]

Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits

BIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 5 2004
Yu C. Kim
Abstract The pharmacokinetics and pharmacodynamics of torasemide were evaluated after intravenous administration of the same total dose of torasemide at a dose of 1mg/kg to rabbits with different infusion times, 1 min (treatment I), 30 min (treatment II) and 2 h (treatment III). The loss of water and electrolytes in urine induced by torasemide was immediately replaced with infusion of an equal volume of lactated Ringer's solution. All the pharmacokinetic parameters of torasemide, such as total area under the plasma concentration,time curve from time zero to time infinity (AUC), total body clearance (CL), apparent volume of distribution at steady state (Vss), terminal half-life and mean residence time (MRT), were independent of infusion times. However, the 8h urine output (235, 534 and 808 ml) and 8h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 µg) were not significantly different among the three treatments. This could be due to the higher diuretic efficiencies in treatments II and III. Copyright © 2004 John Wiley & Sons, Ltd. [source]

Effect of dose and input rate on the brain penetration of BMS-204352 following intravenous administration to rats

BIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 6 2002
Rajesh Krishna
Abstract BMS-204352 is a novel maxi-K channel opener that is being developed for the treatment for stroke. The current study was designed to evaluate the plasma and brain pharmacokinetics of BMS-204352 in rats, in particular, assessing the effect of dose and input rate on brain penetration of BMS-204352. Rats (3 animals/group/time point) received a single intravenous dose of BMS-204352 as 5 mg/kg bolus, 5 mg/kg 30 min infusion, 5 mg/kg 60 min infusion, and 10 mg/kg bolus dose, into the jugular vein. Terminal blood (for plasma) and brain samples were collected for up to 9 h post-dose and samples were analyzed for the concentrations of intact BMS-204352 using a validated liquid chromatographic tandem mass spectrometric method (LC/MS/MS). As dose increased from 5 to 10 mg/kg, both BMS-204352 Cmax and AUC values increased in plasma and brain, somewhat greater in proportion to the increment in dose. Whereas the peak concentrations of BMS-204352 were affected by infusion time, overall AUCs were comparable across the bolus and infusion groups. Terminal disposition (T -half ranged from 1.6 to 2.7 h) of BMS-204352 was unaltered as a function of input rate. BMS-204352 crossed the blood,brain barrier with brain-to-plasma (B/P) ratios of approximately 7,11. Brain-to-plasma ratios appeared to be independent of dose and infusions produced somewhat higher brain penetration (B/P of ca. 11) as compared to bolus (B/P of ca. 7,8) dose. The decline of BMS-204352 in the brain paralleled that of plasma independent of the input rate and dose. Copyright © 2002 John Wiley & Sons, Ltd. [source]

Effectiveness and cost of bisphosphonate therapy in tumor bone disease

CANCER, Issue S3 2003
Jean-Jacques Body M.D., Ph.D.
Abstract BACKGROUND Tumor-induced osteolysis due to breast carcinoma and myeloma is responsible for a considerable morbidity that severely impairs patients'quality of life. Osteoclast-mediated bone resorption is reported to be increased markedly in patients with tumor bone disease and can be inhibited by bisphosphonate therapy. METHODS The incidence of skeletal complications and the effectiveness of bisphosphonate therapy in patients with breast carcinoma metastatic to bone or in those with myeloma were derived from large-scale, long-term, placebo-controlled trials with clodronate or pamidronate. To the authors' knowledge, there are few studies published to date evaluating the cost-effectiveness of bisphosphonate therapy, and the majority that do exist often are based on models and are applicable only to a particular health care system. RESULTS From the placebo groups of the above-mentioned trials, one can estimate that approximately 25,40% of the patients with breast carcinoma metastatic to bone will require radiotherapy for bone pain and approximately 17,50% will sustain incident vertebral fractures yearly. The incidence of complications is reported to be lower in myeloma patients. The prolonged administration of bisphosphonates reportedly can reduce the frequency of skeletal-related events by approximately 25,50%. Maximal efficacy appears to have been achieved with the current therapeutic schemes based on monthly intravenous infusions. Beneficial effects appear to be obtained more readily using the intravenous route rather than the oral route. The costs of bisphosphonate therapy appear to be higher than the cost savings from the prevention of skeletal-related events. The costs per quality of life-adjusted year have been estimated to be > $100,000, but more research is needed. Limited data suggest that zoledronic acid will not reduce treatment costs but the short infusion time will lead to substantial time savings for patients and for outpatient oncology facilities. CONCLUSIONS As is the case for many agents used in oncology, bisphosphonates remain a relatively expensive therapy. More studies are needed to evaluate their cost-effectiveness ratio correctly. A ceiling effect has been reached with current therapeutic schemes and tailoring therapy to the individual patient needs to be evaluated correctly to increase therapeutic effectiveness and improve quality of life further without increasing treatment costs. Cancer 2003;97(3 Suppl):859,65. © 2003 American Cancer Society. DOI 10.1002/cncr.11139 [source]